Otsuka’s VOYXACT Wins FDA Accelerated Approval for IgAN, First APRIL Blocker
Otsuka Pharmaceutical (OTCMKTS: OTSKY) announced that VOYXACT (sibeprenlimab‑szsi) received U.S. FDA Accelerated Approval for reducing...
Otsuka Pharmaceutical
4D Molecular Transfers Asia‑Pacific Gene‑Therapy Rights to Otsuka for $85 M Cash
4D Molecular Therapeutics (4DMT) sold the Asia‑Pacific rights to its eye‑gene therapy 4D‑150 to Otsuka...
Otsuka to Acquire Cantargia’s IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases
Japan-based drug maker Otsuka (OTCMKTS: OTSKY) is set to acquire from Swedish biotech Cantargia AB...
Harbour BioMed and Otsuka Pharma Collaborate Globally on BCMAxCD3 Bispecific T-cell Engager
China-based Harbour BioMed (HKG: 2142) has entered into a global strategic collaboration with Japan-headquartered Otsuka...
Otsuka Files FDA Application for Sibeprenlimab in IgAN Treatment
Japan-based Otsuka Pharmaceutical Co., Ltd. announced the filing of a Biologics License Application (BLA) with...
Otsuka and Lundbeck Win EU Approval for Rxulti in Adolescent Schizophrenia
Japan-based Otsuka Pharmaceutical Co., Ltd and its Danish partner Lundbeck A/S (OTCMKTS: HLUBF) jointly announced...
Otsuka Holdings Weighs Sale of Stake in Medical Device Maker MicroPort Scientific
Otsuka Holdings Co., a Japanese pharmaceutical and healthcare company, is reportedly considering the sale of...
Otsuka Pharmaceutical to Acquire US Biotech Jnana Therapeutics in $1.1 Billion Deal
Otsuka Pharmaceutical Co., Ltd, a leading Japanese pharmaceutical company, has announced the signing of a...
Pharmaceutical Giants Face UK Industry Code Breach Allegations, Including Novartis and Pfizer
Several multinational pharmaceutical corporations have been reprimanded for violating the UK’s Prescription Medicines Code, a...
Otsuka and Shape Therapeutics Partner on Ophthalmology Gene Therapies Development
Japan drug maker Otsuka (OTCMKTS: OTSKY) and US firm Shape Therapeutics have announced a strategic...
Sumitomo Pharma and Otsuka’s Ulotaront Fails to Meet Primary Endpoint in Schizophrenia Trials
Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) and Otsuka Pharmaceutical Co., Ltd (FRA: OS1) have...
Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE
The Center for Drug Evaluation (CDE) website has indicated that Huahui Health’s HH-003, Boehringer Ingelheim’s...